Halozyme Therapeutics (HALO) Return on Sales (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for HALO reached as high as 0.01% in Q1 2022 and fell as low as 0.0% in Q4 2025.
• Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2024.
• On a YoY basis, Return on Sales climbed as much as 0 bps in 2022 and fell as far as 2 bps in 2022.
• Year by year, Return on Sales stood at 0.0% in 2022, then climbed by 17 bps to 0.0% in 2023, then rose by 24 bps to 0.0% in 2024, then slumped by 168 bps to 0.0% in 2025, then surged by 227 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.